NGNE Latest Press Releases

-- November 3, 2026 --

Neurogene to Participate in Upcoming Investor Conferences Business Wire 7:30 AM

-- October 27, 2026 --

Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome Business Wire 7:30 AM

-- October 20, 2026 --

Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress Business Wire 7:30 AM

-- October 5, 2026 --

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:01 PM

-- September 8, 2026 --

Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference Business Wire 7:30 AM

-- September 4, 2026 --

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:01 PM

-- August 11, 2026 --

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates Business Wire 7:30 AM

-- August 4, 2026 --

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:01 PM

-- July 28, 2026 --

Newleos Names Rohan Palekar as Board Chairman Business Wire 7:00 AM

-- July 6, 2026 --

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:01 PM

-- July 1, 2026 --

Neurogene Inc. Announces Pricing of $125 Million Public Offering Business Wire 7:00 AM

-- June 30, 2026 --

Neurogene Inc. Announces Proposed Public Offering Business Wire 4:01 PM

-- June 29, 2026 --

Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome Business Wire 7:00 AM

-- June 8, 2026 --

Neurogene Announces Successful Completion of Dosing in Embolden Registrational Trial of NGN-401 for Rett Syndrome Business Wire 7:30 AM

Market Data Delayed 15 Minutes